PL3254695T3 - Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu - Google Patents

Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu

Info

Publication number
PL3254695T3
PL3254695T3 PL17171169T PL17171169T PL3254695T3 PL 3254695 T3 PL3254695 T3 PL 3254695T3 PL 17171169 T PL17171169 T PL 17171169T PL 17171169 T PL17171169 T PL 17171169T PL 3254695 T3 PL3254695 T3 PL 3254695T3
Authority
PL
Poland
Prior art keywords
cancer
treatment
combination therapy
antibodies against
therapy involving
Prior art date
Application number
PL17171169T
Other languages
English (en)
Inventor
Ugur Sahin
Özlem TÜRECI
Rita Mitnacht-Kraus
Stefan Denis JACOBS
Magdalena Jadwiga UTSCH
Cornelia Adriana Maria HEINZ
Christiane Regina STADLER
Original Assignee
Astellas Pharma Inc.
Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52544200&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3254695(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2012/002210 external-priority patent/WO2013174403A1/en
Application filed by Astellas Pharma Inc., Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh filed Critical Astellas Pharma Inc.
Publication of PL3254695T3 publication Critical patent/PL3254695T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL17171169T 2012-05-23 2013-05-21 Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu PL3254695T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2012/002210 WO2013174403A1 (en) 2012-05-23 2012-05-23 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
PCT/EP2013/001504 WO2013174510A1 (en) 2012-05-23 2013-05-21 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP17171169.0A EP3254695B1 (en) 2012-05-23 2013-05-21 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP13724523.9A EP2852408B1 (en) 2012-05-23 2013-05-21 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

Publications (1)

Publication Number Publication Date
PL3254695T3 true PL3254695T3 (pl) 2021-04-06

Family

ID=52544200

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17171169T PL3254695T3 (pl) 2012-05-23 2013-05-21 Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu
PL13724523T PL2852408T3 (pl) 2012-05-23 2013-05-21 Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13724523T PL2852408T3 (pl) 2012-05-23 2013-05-21 Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu

Country Status (9)

Country Link
EP (6) EP4556071A3 (pl)
CY (2) CY1119549T1 (pl)
DK (1) DK3254695T3 (pl)
HR (1) HRP20171218T1 (pl)
ME (1) ME02932B (pl)
PL (2) PL3254695T3 (pl)
RS (1) RS56187B1 (pl)
SI (1) SI2852408T1 (pl)
SM (1) SMT201700387T1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4556071A3 (en) 2012-05-23 2025-08-27 Astellas Pharma, Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CA3089653A1 (en) * 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
JP2022511394A (ja) 2018-09-30 2022-01-31 カファ セラピューティクス リミテッド Ｃｌｄｎ１８の抗体及び化学療法薬の併用療法
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN111978402B (zh) * 2019-05-24 2022-06-28 三优生物医药(上海)有限公司 新型cldn18.2结合分子
CN111704669B (zh) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 一种用于治疗晚期胃癌的抗cldn18全人源化抗体
CN112480248B (zh) * 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
CN114685670B (zh) * 2020-12-31 2025-06-27 上海莱馥医疗科技有限公司 Cldn18.2抗体及其应用
CN115073596B (zh) * 2021-03-10 2025-06-27 上海莱馥医疗科技有限公司 一种人源化Claudin18.2抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
PL216630B1 (pl) 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
EP2316026A1 (en) * 2008-07-25 2011-05-04 Merck Patent GmbH Method of determination of receptor binding saturation effected by monoclonal antibodies
WO2011090005A1 (ja) * 2010-01-19 2011-07-28 協和発酵キリン株式会社 大腸癌の治療用医薬および治療方法
EP4556071A3 (en) 2012-05-23 2025-08-27 Astellas Pharma, Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

Also Published As

Publication number Publication date
CY1119549T1 (el) 2018-03-07
EP4556070A3 (en) 2025-08-27
EP4556071A2 (en) 2025-05-21
EP3791896B1 (en) 2024-01-10
EP2852408A1 (en) 2015-04-01
EP3791896A1 (en) 2021-03-17
CY1123593T1 (el) 2022-03-24
EP4364756A3 (en) 2024-07-31
RS56187B1 (sr) 2017-11-30
PL2852408T3 (pl) 2017-12-29
EP4556070A2 (en) 2025-05-21
EP4556071A3 (en) 2025-08-27
ME02932B (me) 2018-04-20
SMT201700387T1 (it) 2017-09-07
SI2852408T1 (sl) 2017-10-30
DK3254695T3 (da) 2020-11-30
EP3254695B1 (en) 2020-09-09
EP2852408B1 (en) 2017-05-17
EP4364756A2 (en) 2024-05-08
EP3254695A1 (en) 2017-12-13
HRP20171218T1 (hr) 2017-10-20

Similar Documents

Publication Publication Date Title
IL279330A (en) Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer
IL276434A (en) Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer
IL239981A0 (en) Combined therapy involving antibodies against claudin 18.2 for the treatment of cancer
IL240060A0 (en) Treatment involving antibodies against claudin 2. 18 for the treatment of cancer
SMT201900024T1 (it) Terapia combinata per il trattamento di cancro
SI2852408T1 (sl) Kombinacijska terapija, ki vključuje protitelesa proti claudin 18.2 za zdravljenje raka
IL263781A (en) Combined treatment of ovarian cancer
SMT202200458T1 (it) Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
SI2976360T1 (sl) Terapija, ki vključuje protitelesa proti Klavdinu 18.2 za zdravljenje raka
IL233495A0 (en) Combination for cancer treatment